Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, May 29th.
Several other research firms have also recently issued reports on EYPT. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Friday, April 13th. Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Tuesday, April 17th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Eyepoint Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $6.25.
Eyepoint Pharmaceuticals traded down $0.02, hitting $2.03, on Tuesday, according to MarketBeat.com. 266,683 shares of the company’s stock traded hands, compared to its average volume of 615,587. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 1.57. Eyepoint Pharmaceuticals has a 1-year low of $0.93 and a 1-year high of $2.88. The stock has a market cap of $119.41 million, a price-to-earnings ratio of -3.90 and a beta of 0.81.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Tuesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Eyepoint Pharmaceuticals had a negative net margin of 843.54% and a negative return on equity of 246.01%. The firm had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.69 million. analysts forecast that Eyepoint Pharmaceuticals will post -0.48 EPS for the current year.
In related news, major shareholder Ew Healthcare Partners, L.P. purchased 8,606,324 shares of the business’s stock in a transaction that occurred on Wednesday, March 28th. The stock was bought at an average price of $1.10 per share, with a total value of $9,466,956.40. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 18.91% of the stock is currently owned by insiders.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.